Shire’s $30bn move on Baxalta
Pharma giant Shire has made an unsolicited $30bn all-share offer for America’s Baxalta.

Pharmaceuticals giant Shire, Dublin-based and UK-listed, has made an unsolicited $30bn all-share offer for America's Baxalta. Shire said a tie-up with Baxalta would produce a group with $20bn in sales by 2020. Shire's shares fell on the news. The pharma mergers and acquisitions boom shows no sign of cooling: $400bn of transactions have been announced since January, 80% up from the same period in 2014.
What the commentators said
But there's also "a fair slug of industrial logic", said Neil Unmack on breakingviews.com. Putting the two groups together should produce a strong presence in haemophilia, and as it grows its global presence, it will gain the scale to invest in new drugs, boost prices and beef up marketing, with a view to becoming a leader in rare disease drugs. Yet Shire shareholders seem unconvinced, said Helen Thomas in The Wall Street Journal.
One worry is that Baxalta's haemophilia drugs, which account for half of sales, are about to face competition. What's more, the price is worth a hefty 16 times operating earnings, and is only likely to go higher as negotiations get underway. Shire's recent appetite for "ever bigger, more risky dealmaking is testing investors' tolerance".